DMAA, short for 1,3-dimethylamylamine and also sold under the name methylhexanamine, is a stimulant that was once common in pre workout and weight loss supplements. The U.S. Food and Drug Administration describes DMAA as an amphetamine derivative that is not a legal dietary ingredient, and products marketed as dietary supplements that contain it violate federal law. That single fact, that DMAA is chemically related to amphetamine, is the reason employers and testers ask whether it can register on a standard drug test and whether it can be confused with amphetamine or methamphetamine use.
This article explains how DMAA interacts with the screening tests employers actually use, what a positive amphetamine screen does and does not mean when DMAA is a possible source, and why confirmation testing and medical review exist to sort out exactly this kind of question. It does not explain how to avoid detection, and it is not medical or legal advice.
What DMAA actually is
DMAA was once used in an approved nasal decongestant decades ago, but the FDA states plainly that it is no longer approved for that or any other medical use, and the agency has found no reliable evidence that DMAA occurs naturally in plants despite marketing claims that called it a "natural" stimulant or geranium extract. Since 2012 the FDA has sent warning letters, detained products, and pursued seizure actions against companies that sold DMAA in pre workout and weight loss formulas, including well known brand name products that were pulled from the market. The agency's concern is cardiovascular: DMAA can narrow blood vessels and raise blood pressure, and it has been associated with reports ranging from shortness of breath to heart attack and seizures. None of that enforcement history changes the fact that DMAA can still turn up in gray market or imported supplements, which is why workplace testing programs continue to see occasional cases.
How amphetamine screening tests work
Workplace and clinical drug tests almost always start with an immunoassay, a chemical screen built around antibodies that bind to a target drug and to molecules that share a similar structure. MedlinePlus, a consumer health service of the National Library of Medicine, explains that an initial screening result can be a false positive if the sample reacts with other chemicals from medicines, supplements, or foods, and that any positive screen is followed by a confirmatory test that is more specific and more accurate. That two step design, a fast immunoassay screen followed by a slower, more precise confirmation, is the backbone of essentially every drug testing program, whether it runs on a urine cup, a dip card, or an oral fluid device.
Amphetamine type immunoassays are built to detect molecules that share the core amphetamine structure. Because DMAA is itself an amphetamine derivative, it has a structural resemblance to the target analyte that some amphetamine immunoassays are designed to catch, and there have been published and reported cases of DMAA producing a positive result on an amphetamine class screen, alongside separate reports of DMAA being confirmed as a true positive in testing programs that specifically looked for it, including sports and military drug testing programs. Because DMAA is not a controlled substance and is not itself a federally regulated drug test analyte, it is not part of the standard five panel federal workplace drug testing menu, and a standard amphetamine immunoassay was never designed with DMAA in mind. Any apparent interaction is a side effect of chemical similarity, not an intended target.
Screening versus confirmation
This is the point where the distinction between a screen and a confirmation test matters most. An immunoassay screen is a yes or no chemical reaction, fast and inexpensive, but it cannot by itself tell a reviewer whether the reacting molecule was amphetamine, methamphetamine, a legitimate prescription stimulant, or an unrelated compound like DMAA. A confirmation method such as gas chromatography mass spectrometry, commonly called GC/MS, or liquid chromatography mass spectrometry, separates and identifies the exact molecule present rather than just detecting a class reaction. GC/MS can distinguish DMAA from amphetamine and methamphetamine because the molecules have different structures and different mass spectral signatures, even though an immunoassay screen might not make that distinction on its own. No employer or lab should treat a non confirmed screening result as a final determination of amphetamine or methamphetamine use.
| Step | Method | What it shows | Limitation |
|---|---|---|---|
| Initial screen | Immunoassay (cup, dip card, or instrument) | Presumptive positive or negative for a drug class | Can react to structurally similar compounds, cannot identify the exact substance |
| Confirmation | GC/MS or LC/MS | Identifies the specific molecule and quantity present | Requires a laboratory and more time than a point of collection screen |
| Medical review | Medical Review Officer interview | Determines whether a confirmed positive has a legitimate explanation | Relies on the donor providing documentation when applicable |
What happens after a positive screen
In a properly run program, a nonnegative immunoassay screen is never the end of the process. The sample goes to a certified laboratory for confirmation, and if the confirmation is positive, a Medical Review Officer reviews the laboratory result. SAMHSA describes the Medical Review Officer, or MRO, as a licensed physician trained in drug testing science, substance use disorders, and the applicable federal regulations, whose job is to interpret and evaluate a confirmed result together with the donor's medical history and any legitimate explanation before a result is reported to an employer as verified positive. If an employee believes a supplement containing DMAA, or any other substance, caused an unexpected result, that explanation belongs in the MRO interview and documentation process, not in a dispute with a collector or an assumption at the point of collection.
Employers that run their own drug free workplace programs, including those that follow the federal model described on SAMHSA's drug free workplace program page, generally rely on this same screen, confirm, and review structure regardless of which specific compound might be involved. The design exists precisely to prevent a chemical cross reaction, whatever its source, from becoming an unreviewed adverse employment action.
Why this matters for employers using point of collection tests
Employers who run their own point of collection screening, such as urine test cups or dip cards that include an amphetamine (AMP) panel, should know that a nonnegative screen is a presumptive result only. A program that sends every nonnegative screen to a certified laboratory for GC/MS or LC/MS confirmation, and that routes every confirmed positive through an MRO review, protects both the accuracy of the program and the rights of the person being tested. This applies whether the suspected interference is DMAA, a legitimate prescription stimulant, or any other amphetamine class compound. Employers sourcing amphetamine panel cups, dip cards, or oral fluid devices for a workplace program can review options in the drug test cup collection, and programs that want more background on how the amphetamine panel itself is structured can read what is AMP on a drug test and the related guide on whether pre workout products in general can show up on a drug test.
What this is not
This article does not suggest that DMAA is a reliable explanation to offer after a positive test, and it does not suggest any way to interfere with, dilute, or otherwise defeat a screening or confirmation test. DMAA remains an unapproved, illegal ingredient in dietary supplements according to the FDA, and anyone concerned about an unexpected test result should raise it through the MRO review process with documentation of what was actually taken, not through self diagnosis. Employers should rely on their MRO and certified laboratory, not on assumptions about any single supplement ingredient, to resolve a confirmed positive.
Frequently asked questions
Is DMAA illegal?
The FDA states that DMAA is not a legal dietary ingredient and that dietary supplements marketed with DMAA violate federal law, though DMAA is not a federally scheduled controlled substance in the way that amphetamine and methamphetamine are.
Can DMAA cause a false positive on an amphetamine drug test?
Because DMAA is structurally an amphetamine derivative, some amphetamine class immunoassay screens have reportedly reacted to it, and there are also reports of DMAA itself being detected as a true finding in testing programs that specifically screen for it. A confirmation test such as GC/MS can distinguish DMAA from amphetamine and methamphetamine.
Does a standard five panel workplace drug test look for DMAA specifically?
No. DMAA is not part of the standard federal five panel menu. Any interaction with an amphetamine screen would come from structural cross reactivity on the immunoassay, not from the panel being designed to detect DMAA.
What should an employee do if they believe a supplement caused a positive result?
Any explanation for a confirmed positive belongs with the Medical Review Officer during the verification interview, where the donor can provide information about medications or products taken. The MRO, not the collector or the employer, makes the determination of whether a confirmed result is verified.
What is the difference between a screening test and a confirmation test?
A screening immunoassay gives a fast presumptive result based on a chemical reaction to a class of drugs. A confirmation test, typically GC/MS or LC/MS, identifies the specific molecule present and is used to verify any nonnegative screen before it is reported as a confirmed result.
Can an employer be sure a positive amphetamine screen means illegal drug use?
Not from the screen alone. A nonnegative screen is presumptive and should always be confirmed at a certified laboratory and reviewed by an MRO before any employment decision is made.
This article is general information for workplace drug testing programs and is not legal or medical advice. Employers should consult qualified counsel and their Medical Review Officer for decisions involving specific test results.
